###begin article-title 0
###xml 77 80 77 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Inflammation, Insulin Resistance, and Diabetes-Mendelian Randomization Using CRP Haplotypes Points Upstream
###end article-title 0
###begin article-title 1
More Evidence Against a Causal Association between C-Reactive Protein and Diabetes
###end article-title 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 378 381 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Raised C-reactive protein (CRP) is a risk factor for type 2 diabetes. According to the Mendelian randomization method, the association is likely to be causal if genetic variants that affect CRP level are associated with markers of diabetes development and diabetes. Our objective was to examine the nature of the association between CRP phenotype and diabetes development using CRP haplotypes as instrumental variables.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 929 932 929 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 987 988 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1255 1256 1255 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1291 1294 1291 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1393 1394 1393 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 132 135 <span type="species:ncbi:9606">men</span>
###xml 140 145 <span type="species:ncbi:9606">women</span>
We genotyped three tagging SNPs (CRP + 2302G > A; CRP + 1444T > C; CRP + 4899T > G) in the CRP gene and measured serum CRP in 5,274 men and women at mean ages 49 and 61 y (Whitehall II Study). Homeostasis model assessment-insulin resistance (HOMA-IR) and hemoglobin A1c (HbA1c) were measured at age 61 y. Diabetes was ascertained by glucose tolerance test and self-report. Common major haplotypes were strongly associated with serum CRP levels, but unrelated to obesity, blood pressure, and socioeconomic position, which may confound the association between CRP and diabetes risk. Serum CRP was associated with these potential confounding factors. After adjustment for age and sex, baseline serum CRP was associated with incident diabetes (hazard ratio = 1.39 [95% confidence interval 1.29-1.51], HOMA-IR, and HbA1c, but the associations were considerably attenuated on adjustment for potential confounding factors. In contrast, CRP haplotypes were not associated with HOMA-IR or HbA1c (p = 0.52-0.92). The associations of CRP with HOMA-IR and HbA1c were all null when examined using instrumental variables analysis, with genetic variants as the instrument for serum CRP. Instrumental variables estimates differed from the directly observed associations (p = 0.007-0.11). Pooled analysis of CRP haplotypes and diabetes in Whitehall II and Northwick Park Heart Study II produced null findings (p = 0.25-0.88). Analyses based on the Wellcome Trust Case Control Consortium (1,923 diabetes cases, 2,932 controls) using three SNPs in tight linkage disequilibrium with our tagging SNPs also demonstrated null associations.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
Observed associations between serum CRP and insulin resistance, glycemia, and diabetes are likely to be noncausal. Inflammation may play a causal role via upstream effectors rather than the downstream marker CRP.
###end p 7
###begin p 8
Using a Mendelian randomization approach, Eric Brunner and colleagues show that the associations between serum C-reactive protein and insulin resistance, glycemia, and diabetes are likely to be noncausal.
###end p 8
###begin title 9
Editors' Summary
###end title 9
###begin title 10
Background.
###end title 10
###begin p 11
###xml 195 201 <span type="species:ncbi:9606">people</span>
###xml 719 725 <span type="species:ncbi:9606">people</span>
Diabetes-a common, long-term (chronic) disease that causes heart, kidney, nerve, and eye problems and shortens life expectancy-is characterized by high levels of sugar (glucose) in the blood. In people without diabetes, blood sugar levels are controlled by the hormone insulin. Insulin is released by the pancreas after eating and "instructs" insulin-responsive muscle and fat cells to take up the glucose from the bloodstream that is produced by the digestion of food. In the early stages of type 2 diabetes (the commonest type of diabetes), the muscle and fat cells become nonresponsive to insulin (a condition called insulin resistance), and blood sugar levels increase. The pancreas responds by making more insulin-people with insulin resistance have high blood levels of both insulin and glucose. Eventually, however, the insulin-producing cells in the pancreas start to malfunction, insulin secretion decreases, and frank diabetes develops.
###end p 11
###begin title 12
Why Was This Study Done?
###end title 12
###begin p 13
###xml 1065 1068 1065 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 28 34 <span type="species:ncbi:9606">people</span>
###xml 410 416 <span type="species:ncbi:9606">people</span>
###xml 705 711 <span type="species:ncbi:9606">people</span>
###xml 791 797 <span type="species:ncbi:9606">people</span>
Globally, about 200 million people have diabetes, but experts believe this number will double by 2030. Ways to prevent or delay the onset of diabetes are, therefore, urgently needed. One major risk factor for insulin resistance and diabetes is being overweight. According to one theory, increased body fat causes mild, chronic tissue inflammation, which leads to insulin resistance. Consistent with this idea, people with higher than normal amounts of the inflammatory protein C-reactive protein (CRP) in their blood have a high risk of developing diabetes. If inflammation does cause diabetes, then drugs that inhibit CRP might prevent diabetes. However, simply measuring CRP and determining whether the people with high levels develop diabetes cannot prove that CRP causes diabetes. Those people with high blood levels of CRP might have other unknown factors in common (confounding factors) that are the real causes of diabetes. In this study, the researchers use "Mendelian randomization" to examine whether increased blood CRP causes diabetes. Some variants of CRP (the gene that encodes CRP) increase the amount of CRP in the blood. Because these variants are inherited randomly, there is no likelihood of confounding factors, and an association between these variants and the development of insulin resistance and diabetes indicates, therefore, that increased CRP levels cause diabetes.
###end p 13
###begin title 14
What Did the Researchers Do and Find?
###end title 14
###begin p 15
###xml 673 676 673 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 978 981 978 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1068 1071 1068 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1225 1228 1225 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1354 1357 1354 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 61 67 <span type="species:ncbi:9606">people</span>
###xml 461 467 <span type="species:ncbi:9606">people</span>
###xml 691 702 <span type="species:ncbi:9606">participant</span>
The researchers measured blood CRP levels in more than 5,000 people enrolled in the Whitehall II study, which is investigating factors that affect disease development. They also used the "homeostasis model assessment-insulin resistance" (HOMA-IR) method to estimate insulin sensitivity from blood glucose and insulin measurements, and measured levels of hemoglobin A1c (HbA1c, hemoglobin with sugar attached-a measure of long-term blood sugar control) in these people. Finally, they looked at three "single polynucleotide polymorphisms" (SNPs, single nucleotide changes in a gene's DNA sequence; combinations of SNPs that are inherited as a block are called haplotypes) in CRP in each study participant. Common haplotypes of CRP were related to blood serum CRP levels and, as previously reported, increased blood CRP levels were associated with diabetes and with HOMA-IR and HbA1c values indicative of insulin resistance and poor blood sugar control, respectively. By contrast, CRP haplotypes were not related to HOMA-IR or HbA1c values. Similarly, pooled analysis of CRP haplotypes and diabetes in Whitehall II and another large study on health determinants (the Northwick Park Heart Study II) showed no association between CRP variants and diabetes risk. Finally, data from the Wellcome Trust Case Control Consortium also showed no association between CRP haplotypes and diabetes risk.
###end p 15
###begin title 16
What Do These Findings Mean?
###end title 16
###begin p 17
Together, these findings suggest that increased blood CRP levels are not responsible for the development of insulin resistance or diabetes, at least in European populations. It may be that there is a causal relationship between CRP levels and diabetes risk in other ethnic populations-further Mendelian randomization studies are needed to discover whether this is the case. For now, though, these findings suggest that drugs targeted against CRP are unlikely to prevent or delay the onset of diabetes. However, they do not discount the possibility that proteins involved earlier in the inflammatory process might cause diabetes and might thus represent good drug targets for diabetes prevention.
###end p 17
###begin title 18
Additional Information.
###end title 18
###begin p 19
Please access these Web sites via the online version of this summary at .
###end p 19
###begin p 20
###xml 37 50 37 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLoS Medicine</italic>
This study is further discussed in a PLoS Medicine by Bernard Keavney
###end p 20
###begin p 21
The MedlinePlus encyclopedia provides information about  and about  (in English and Spanish)
###end p 21
###begin p 22
###xml 77 84 <span type="species:ncbi:9606">patient</span>
US National Institute of Diabetes and Digestive and Kidney Diseases provides patient information on , including information on  (in English and Spanish)
###end p 22
###begin p 23
The International Diabetes Federation provides information about , including information on the
###end p 23
###begin p 24
The US Centers for Disease Control and Prevention provides information for the public and professionals on all aspects of  (in English and Spanish)
###end p 24
###begin p 25
Wikipedia has a page on  (note: Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
###end p 25
###begin title 26
Introduction
###end title 26
###begin p 27
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b001">1</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b003">3</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b004">4</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b010">10</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b011">11</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b012">12</xref>
C-reactive protein (CRP) is a nonspecific marker of systemic inflammation that predicts incident type 2 diabetes. Chronic low-grade inflammation may induce insulin resistance and is a candidate pathway leading from obesity to diabetes [1-3]. Several population-based observational studies suggest an independent role for CRP in the development of insulin resistance and diabetes, but it is unclear whether this association is a causal one or the consequence of imperfect adjustment for adiposity and other confounding factors [4-10]. Preventing or delaying onset of diabetes and its complications is an important therapeutic aim, and there is interest in inflammatory effectors including CRP as drug targets [11,12]. It is therefore highly desirable to establish which mediators in the inflammatory cascade are causal for diabetes.
###end p 27
###begin p 28
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b013">13</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b014">14</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b015">15</xref>
###xml 793 795 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b013">13</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b016">16</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b017">17</xref>
Mendelian randomization involves comparison of phenotype and genotype effects in observational studies [13]. If the association between a modifiable risk factor and disease is causal, the genetic variant associated with this risk factor should be related to the disease outcome to the extent predicted by the magnitude of its association with the risk factor. The approach is based on two concepts. First, random allocation of parental alleles leads to lifetime exposure to differing levels of the risk factor, in the present case CRP haplotype and heritable CRP level [14,15]. Second, the genetically influenced component of variation in the risk factor will generally be unaffected by confounding and reverse causation, in contrast to the variation associated with environmental influences [13,16,17].
###end p 28
###begin p 29
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b004">4</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b018">18</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b019">19</xref>
###xml 1018 1021 1018 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
We are aware of one previous study of CRP and diabetes employing the Mendelian randomization technique in a European population [4]. It found that a rare haplotype was associated with a modest increase in risk of diabetes but did not employ instrumental variables analysis to show that the effect of circulating CRP on diabetes risk was unconfounded. Confounding was demonstrated in a study of CRP and metabolic syndrome variables [18]. The present study examines the causal nature of the relation between serum CRP and development of diabetes risk using Mendelian randomization. We measured homeostasis model assessment-insulin resistance (HOMA-IR) [19] and hemoglobin A1c (HbA1c) as an index of glycemic control, as well as determining diabetes caseness, in the Whitehall II Study. The continuous traits provide adequate statistical power for an instrumental analysis of the unconfounded and unbiased (by reverse causation and regression dilution bias) effects of CRP on HbA1c and HOMA-IR. Three tagging SNPs in the CRP gene allowed construction of haplotypes that were used as instrumental variables. We carried out a pooled analysis in relation to diabetes caseness as the same haplotypes were available in the prospective Northwick Park Heart Study II (NPHSII). Data from the Wellcome Trust Case Control Consortium (WTCCC) further allowed us to analyze three SNPs in tight long-range linkage disequilibrium (LD) with our tagging SNPs among 1,923 diabetes cases and 2,932 controls.
###end p 29
###begin title 30
Methods
###end title 30
###begin title 31
Index Study: Whitehall II Study
###end title 31
###begin p 32
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b020">20</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b021">21</xref>
###xml 377 380 377 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 493 496 493 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 226 238 <span type="species:ncbi:9606">participants</span>
###xml 573 576 <span type="species:ncbi:9606">men</span>
###xml 584 589 <span type="species:ncbi:9606">women</span>
###xml 591 603 <span type="species:ncbi:9606">participants</span>
###xml 739 742 <span type="species:ncbi:9606">men</span>
###xml 750 755 <span type="species:ncbi:9606">women</span>
In 1985-1988, all nonindustrial civil servants aged between 35 and 55 y, in 20 departments in central London were invited to a medical examination at their workplace [20,21]. With 73% participation, the cohort included 10,308 participants at study entry. Of these individuals, 6,156 participated in screening in 2003-2004 (study phase 7) and were genotyped for variants in the CRP gene. Excluding non-Europeans, those with missing phase 7 CRP, neither HOMA-IR nor HbA1c concentration, missing CRP SNPs, or with unreliable haplotypes, the final sample included 5,274 (3,849 men, 1,425 women) participants aged 50 to 74 y (mean 61 y), all of whom signed an informed consent. CRP measurements at mean age 49 y were available for 4,674 (3,433 men, 1,241 women).
###end p 32
###begin title 33
Measurements.
###end title 33
###begin p 34
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b022">22</xref>
###xml 373 384 <span type="species:ncbi:9606">participant</span>
###xml 540 552 <span type="species:ncbi:9606">participants</span>
###xml 1088 1098 <span type="species:ncbi:10141">guinea pig</span>
Age, sex, body mass index (BMI), waist circumference, blood pressure, smoking, physical activity, socioeconomic position, coronary heart disease, and diabetes status were measured at mean ages 49 and 61 y. Weight was measured in underwear to the nearest 0.1 kg on Soehnle electronic scales. Height was measured in bare feet to the nearest 1 mm using a stadiometer with the participant standing erect with head in the Frankfurt plane. Waist circumference, taken as the smallest circumference at or below the costal margin, was measured with participants unclothed in the standing position utilizing a fiberglass tape measure at 600 g tension. Venous blood was taken in the fasting state or at least 5 h after a light, fat-free breakfast, before undergoing a 2-h 75-g oral glucose tolerance test [22]. Serum triglycerides were measured by automated enyzmic colorimetric methods. HDL cholesterol was measured using phosphotungstate precipitation. Glucose was measured in fluoride plasma by an electrochemical glucose oxidase method. Insulin was measured by radioimmunoassay using polyclonal guinea pig antiserum at age 49 y and by double antibody ELISA at age 61 y.
###end p 34
###begin title 35
C-reactive protein genotyping.
###end title 35
###begin p 36
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 382 383 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 523 526 523 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 869 870 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 919 920 919 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 147 159 <span type="species:ncbi:9606">participants</span>
###xml 1076 1088 <span type="species:ncbi:9606">participants</span>
DNA was extracted from blood samples using magnetic bead technology (Geneservice). Using validated genotype data (minor allele frequency >5%) from participants of European descent from the National Heart Lung and Blood Institute (NHLBI) Programs for Genomic Applications (PGA) database (), and HapMap (), we examined the pattern of LD across the CRP gene. We used the haplotype LD r2 method to select a set of tagging (t) SNPs capable of capturing maximum haplotype diversity using TagIT (). We genotyped three SNPs in the CRP gene (+1444T > C [rs1130864]; +2302G > A [rs1205]; and +4899T > G [rs 3093077]) using the ABI Prism 7900HT Sequence Detection System for both PCR and allelic discrimination (Applied Biosystems) under standard conditions. CRP +2303 and +4899 were found to be in Hardy Weinberg Equilibrium (HWE) (chisq p > 0.05), however +1444 was not in HWE (p = 0.003). Blind re-genotyping of the +1444 SNP (n = 678) in a different laboratory produced a mismatch rate of 0.5% suggesting that genotyping errors were not responsible. A repeated blood sample from 553 participants showed the genotyping error rate was <1% for each SNP.
###end p 36
###begin title 37
C-reactive protein.
###end title 37
###begin p 38
###xml 718 719 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 749 750 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 522 534 <span type="species:ncbi:9606">participants</span>
###xml 560 572 <span type="species:ncbi:9606">participants</span>
CRP was measured in serum stored at -80 degreesC using a high-sensitivity immunonephelometric assay in a BN ProSpec nephelometer (Dade Behring). Values below the detection limit (0.154 mg/l) were assigned a value of 0.077 mg/l (333 [7.1%] at age 49 y, 104 [2.0%] at age 61 y). Samples from both study phases were analyzed at the same time. Intra- and interassay coefficients of variation were 4.7% and 8.3%. To measure short-term biological variation and laboratory error, a repeated sample was taken from a subset of 150 participants at mean age 49 y and 533 participants at mean age 61 y (average time between samples 32 and 24 d, respectively). Reliability between samples was assessed with intraclass correlation: r = 0.83 at mean age 49 y, and r = 0.57 at mean age 61 y.
###end p 38
###begin title 39
Diabetes.
###end title 39
###begin p 40
###xml 236 238 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b023">23</xref>
Diabetes status was determined at mean ages 49, 56, and 61 y on the basis of self-report of doctor diagnosis, use of diabetes medication or 75 g OGTT. Diabetes was defined by 2-h glucose >/= 11.1 mmol/l or fasting glucose >/= 7 mmol/l [23].
###end p 40
###begin title 41
HbA1c and HOMA-IR.
###end title 41
###begin p 42
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b019">19</xref>
###xml 343 344 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 299 311 <span type="species:ncbi:9606">participants</span>
HbA1c was measured in EDTA whole blood on a calibrated HPLC system with automated hemolysis prior to injection. HbA1 is resolved as a separate peak, which does not interfere with HbA1c quantitation. HOMA-IR was calculated as (fasting glucose [mmol/l] x fasting insulin [mU/l]/22.5) [19]. Nonfasting participants were assigned a missing value (n = 435, 9.1%).
###end p 42
###begin title 43
Data Analysis
###end title 43
###begin title 44
Standard regression analysis.
###end title 44
###begin p 45
###xml 552 555 552 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
We used age- and sex-adjusted least square regression analysis to assess (1) the association of haplotypes (see below) with circulating CRP levels at baseline and follow-up, and with potential confounding factors; (2) the associations of potential confounding factors with circulating CRP levels and with HbA1c and HOMA-IR at follow-up; and (3) the association between circulating CRP levels with HbA1c and HOMA-IR in a multivariable model. The haplotype-confounder associations were computed to test our underlying hypothesis that genetic variants in CRP would not be associated with confounding factors that effect conventional epidemiological associations. We used Cox regression to assess associations between CRP levels at baseline and incident diabetes, and logistic regression analysis to assess associations between haplotype and prevalent diabetes with a binary indicator for study (Whitehall II or NPHSII) in the pooled analysis.
###end p 45
###begin title 46
Haplotype construction.
###end title 46
###begin p 47
We constructed haplotypes with the genetic data analysis program SIMHAP (see , obtained May 2, 2007), using 1,000 iterations and a posterior probability >/= 0.95. Four haplotypes of SNPs +1444, +2302, and +4899 (CAT, CGG, CGT, and TGT) remained in the analysis in which genetic variants were used to determine the association of CRP with diabetes, HbA1c, and HOMA-IR.
###end p 47
###begin title 48
Instrumental variables analysis.
###end title 48
###begin p 49
###xml 45 48 45 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b018">18</xref>
###xml 612 613 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 703 704 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b024">24</xref>
###xml 297 308 <span type="species:ncbi:9606">participant</span>
An instrumental variables analysis, in which CRP haplotypes were used as instrumental variables for the unconfounded and unbiased effect of CRP on HbA1c, was undertaken using two-stage least squares method. In these analyses we use a model for the haplotype-CRP association that assumes each of a participant's two haplotypes contributes additively to his/her value of CRP, as in a previous study [18]. We compared results from the instrumental variable estimates of the association of CRP with HbA1c to those from ordinary linear regression using the Durbin form of the Durbin-Wu-Hausman statistic. We used the F-statistics from the first-stage regressions to evaluate the strength of the instruments (F > 10 indicates sufficient strength to ensure the validity of instrumental variable methods) [24].
###end p 49
###begin title 50
General analytic procedures.
###end title 50
###begin p 51
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b025">25</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b027">27</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b017">17</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b018">18</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b028">28</xref>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 514 515 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
There was no statistical evidence that the associations we examined differed by sex, although previous studies have been inconsistent in this respect [25-27]. Because of skewness, we logarithmically transformed CRP in the analyses, using log base 2 so that we could present associations per doubling of CRP [17,18,28], and transformed HbA1c and HOMA-IR to the natural logarithm. We excluded observations with serum CRP > 10 mg/l, indicating an acute phase reaction, in analyses with serum CRP (n = 80 at age 49 y, n = 182 at age 61 y). Analyses were performed with Stata 8.2 or 9.2 (Stata Institute).
###end p 51
###begin title 52
Replication Studies
###end title 52
###begin p 53
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b029">29</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b030">30</xref>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b029">29</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b031">31</xref>
###xml 585 586 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 586 587 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 621 622 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 663 664 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 664 665 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 896 897 896 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 146 149 <span type="species:ncbi:9606">men</span>
We replicated our analysis in two independent samples: NPHSII and WTCCC [29,30]. The three tagging SNPs utilized here were typed in NPHSII (2,173 men, mean age 56 y), and cases of diabetes (n = 174) were identified to the end of 2005 by searching medical records for physician diagnosis and treatment [29]. Within the WTCCC sample, none of the SNPs that we have used here were available [31]. However, three alternative SNPs, identified using Ensembl (), were included on the Affymetrix 500K array and are in long-range LD with our tagging SNPs, as follows: rs12760041 with rs1130864 (r2 = 0.84), rs2592889 with rs1205 (r2 = 0.75), and rs11265260 with rs3093077 (r2 = 1.00). An analysis based on 1,923 cases of diabetes and 2,932 controls was used to examine genotype-diabetes associations. Each genotype was found to be in Hardy Weinberg Equilibrium with the exception of rs2592889 among cases (p = 0.003).
###end p 53
###begin title 54
Results
###end title 54
###begin p 55
###xml 137 144 137 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t001">Table 1</xref>
###xml 270 277 270 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t002">Table 2</xref>
###xml 335 336 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 404 405 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 540 547 538 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t003">Table 3</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 61 64 <span type="species:ncbi:9606">men</span>
Participants were on average 60.9 y of age, the majority was men and from executive officer and senior administrative employment grades (Table 1). There were 354 (6.7%) cases of diabetes at follow-up. As expected, haplotypes were associated with circulating CRP levels (Table 2) but not with risk factors at baseline or follow-up (all p >/= 0.07) except in one case at baseline: CGG-occupational status (p = 0.038). In contrast, all risk factors were associated with serum CRP, HbA1c, and HOMA-IR except physical activity level (CRP only) (Table 3).
###end p 55
###begin p 56
###xml 0 11 <span type="species:ncbi:9606">Participant</span>
Participant Characteristics
###end p 56
###begin p 57
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Association between CRP Haplotypes and Serum CRP Concentration
###end p 57
###begin p 58
Contemporaneous Associations of Risk Factors for Diabetes with Serum CRP Concentration, HbA1c, and HOMA-IR at Mean Age 61 y (Adjusted for Age and Sex)
###end p 58
###begin p 59
###xml 182 189 182 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t004">Table 4</xref>
###xml 479 486 479 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t005">Table 5</xref>
Baseline serum CRP was a strong predictor of incident diabetes after adjustment for age and sex (hazard ratio [HR] for doubling of CRP 1.39 (95% confidence interval [CI] 1.29-1.51) (Table 4). Controlling for general and central obesity attenuated the CRP effect considerably, and after extensive adjustment the HR was reduced by 51%. After adjustment for age and sex, higher contemporaneous and previous serum CRP concentrations were associated with increased HOMA-IR and HbA1c (Table 5). Further adjustment for risk factors greatly attenuated these associations.
###end p 59
###begin p 60
###xml 79 91 <span type="species:ncbi:9606">Participants</span>
Relation between Serum CRP at Mean Age 49 y and Incident Type 2 Diabetes among Participants of European Origin during 13.1 y Follow-up
###end p 60
###begin p 61
Prospective and Cross-Sectional Associations of Serum CRP with HbA1c and HOMA-IR
###end p 61
###begin p 62
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t006">Table 6</xref>
Median levels of HbA1c and HOMA-IR did not vary by CRP haplotypes, suggesting that these haplotypes have no effect on diabetes risk (Table 6), although they are consistently associated with serum CRP concentrations.
###end p 62
###begin p 63
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 75 87 <span type="species:ncbi:9606">Participants</span>
Relation between CRP Haplotypes, HOMA-IR, and HbA1c at Mean Age 61 y among Participants of European Origin
###end p 63
###begin p 64
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 305 312 305 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t007">Table 7</xref>
###xml 640 641 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 733 734 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
F-statistics from the first-stage regressions in the instrumental variable models were greater than 10 (HbA1c, 18.3 for contemporaneous and 17.0 for previous serum CRP; HOMA-IR, 15.3 and 15.8, respectively) indicating sufficient strength to ensure validity of instrumental variable methods in these data. Table 7 compares the magnitudes of association of CRP with HbA1c and HOMA-IR obtained from the age- and sex-adjusted ordinary least squares regression analysis and the unadjusted instrumental variables analysis. While the ordinary least squares regression analysis indicated positive associations of CRP levels with HbA1c and HOMA-IR (p < 0.0001), the instrumental variables analysis consistently suggested no such association (p > 0.60), though this was imprecisely estimated. The Durbin-Wu-Hausman test for difference between the linear regression and instrumental variables estimates approached significance in three of four comparisons and highly significant for contemporaneous serum CRP with HOMA-IR as outcome. Coefficients from the confounder-adjusted linear regressions were similar to those from the instrumental variables analyses, suggesting no causal CRP effect.
###end p 64
###begin p 65
###xml 164 167 164 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Comparison of Cross-Sectional and Prospective Associations between CRP and HbA1c Concentration Estimated by Linear Regression and with Instrumental Variables (with CRP Haplotypes as Instruments)
###end p 65
###begin title 66
NPHSII
###end title 66
###begin p 67
###xml 81 89 81 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050155-st001">Table S1</xref>
###xml 233 241 233 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050155-st002">Table S2</xref>
Haplotype-serum CRP associations were similar to those observed in Whitehall II (Table S1). None of the four haplotypes was associated with potential confounding variables age, BMI, systolic BP, serum triglycerides, and cholesterol (Table S2). Serum CRP was a risk factor for incident diabetes (age adjusted HR for doubling of CRP 1.27 [95% CI 1.11-1.44]). The effect was attenuated after controlling for the risk factors above (HR = 1.08 [0.93-1.24]).
###end p 67
###begin p 68
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 127 134 127 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t008">Table 8</xref>
###xml 279 286 279 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050155-t002">Table 2</xref>
Pooled analysis of CRP haplotypes and prevalent cases of diabetes (n = 522) in Whitehall II and NPHSII produced null findings (Table 8). Among TGT homozygotes the reduced risk of diabetes is counterfactual given the direct association between TGT haplotype number and serum CRP (Table 2).
###end p 68
###begin p 69
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Pooled Analysis of Association between CRP Haplotypes and Type 2 Diabetes in Whitehall II and NPHSII
###end p 69
###begin title 70
WTCCC Sample
###end title 70
###begin p 71
Case-control analysis of diabetes and the three SNPs in long-range LD with the SNPs of interest produced no evidence of association. Odds ratios (95% CI) were 0.98 (0.92-1.04) for rs12760041, 1.04 (0.98-1.12) for rs2592889, and 0.91 (0.81-1.03) for rs11265260.
###end p 71
###begin title 72
Discussion
###end title 72
###begin p 73
This large study provides evidence that systemic CRP levels are not responsible for development of insulin resistance, hyperglycemia, or diabetes. The finding does not preclude the possibility that inflammatory signals contribute to causal processes leading to diabetes. We obtained a clear signal, using Mendelian randomization, that the association between systemic CRP and diabetes risk is not causal. However, the nature of the prospective relation between serum CRP and diabetes risk points to the potential effects of more proximal mediators in the inflammatory cascade.
###end p 73
###begin p 74
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Our underlying assumption was confirmed that genetic variants in CRP would not be associated with socioeconomic, lifestyle, and biological confounding factors, enabling us to estimate the unconfounded effect of CRP on HbA1c and HOMA-IR by means of the variation in systemic CRP due to four CRP haplotypes. No such effect was detected.
###end p 74
###begin p 75
###xml 418 421 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
In addition to the analysis of Whitehall II data, further support for our conclusion concerning CRP and diabetes is provided by NPHSII and WTCCC. NPHSII haplotype and disease caseness data allowed a pooled haplotype-diabetes analysis with Whitehall II, which confirmed our null findings. Among almost 2,000 cases of diabetes and 3,000 controls in the WTCCC sample, we were able to identify three SNPs distant from the CRP locus but in tight LD with the SNPs we typed. None of these was associated with diabetes caseness.
###end p 75
###begin p 76
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b013">13</xref>
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b015">15</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b018">18</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b032">32</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b038">38</xref>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b024">24</xref>
###xml 1117 1120 1117 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1265 1268 1265 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1364 1366 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b039">39</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b040">40</xref>
###xml 2099 2101 2099 2101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b041">41</xref>
Several issues may compromise the value of Mendelian randomization approach in assessing causality [13]. First, common genetic variants determining significant proportions of variance in the exposure of interest are needed. For the CRP haplotypes in question, this is the case here and in other independent studies [15,18,32-38]. Second, the association of the genotype (instrumental variable) with phenotype has to be strong enough for the instrumental variables analysis to be consistent. The F-statistic was clearly above the threshold of 10 used to identify the problem of a weak instrument [24], although a larger study would yield greater precision in the estimates from instrumental variables analysis. Third, the Mendelian randomization approach may be open to confounding if the genetic variants used as instruments have multiple effects on phenotype (pleiotropy) or if the variant is in LD with another genetic variant that differently influences the pathway of interest. With respect to the null associations observed in our study we think pleiotropy is unlikely. The variants that we used to generate the CRP haplotypes used here as instrumental variables are in very close LD with variation within a transcription factor binding site located 5' of the CRP gene, which is associated with circulating concentrations of CRP and thought to be functional [39,40]. It is unlikely that the variation in circulating CRP associated with this marker (or those, like our haplotypes, in LD with it) is substantially involved in other phenotypes affecting inflammatory processes because of their role as a transcription factor binding site. Fourth, developmental compensation, or canalization, during fetal development may provide resistance to the influence of a genetic variant through permanent changes in cellular function that counterbalance the genetic effect. Such mechanisms are a potential source of bias in all Mendelian randomization studies. Despite this potential bias, the method has confirmed established associations such as that of LDL cholesterol with cardiovascular disease risk [41].
###end p 76
###begin p 77
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b018">18</xref>
###xml 180 183 180 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b004">4</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b042">42</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b004">4</xref>
###xml 541 544 541 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b042">42</xref>
###xml 590 593 590 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b043">43</xref>
###xml 902 914 <span type="species:ncbi:9606">participants</span>
Our findings are consistent with a previous study that examined HOMA-IR as an outcome [18]. To our knowledge two previous studies have examined the association of variation in the CRP gene in relation to the binary outcome of type 2 diabetes [4,42]. We find that the rare CGG haplotype is associated with serum CRP level, but we do not replicate the modest link with diabetes observed in the Rotterdam study [4]. Among Pima Indians (a population with very high levels of risk for type 2 diabetes) the rs133552 SNP, in the promoter region of CRP, was associated with diabetes risk [42]. The CRP haplotypes used in the present study index the rare allele of rs133552, thus it is unlikely that our null finding is due to unmeasured genetic variation. The consistent lack of association in our primary study, our two replication samples including the large WTCCC, and a large case-control study of Finnish participants [43], provides compelling evidence that CRP is not related to diabetes in European populations. Further replication of the genetic association in the Pima Indian population would shed light on this putative ethnic difference.
###end p 77
###begin p 78
###xml 532 533 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b001">1</xref>
###xml 534 536 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b044">44</xref>
###xml 537 539 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b045">45</xref>
###xml 625 627 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b046">46</xref>
If glucose intolerance and insulin resistance have inflammatory causes, mediators should be sought among cytokines more proximal than CRP to the start of the inflammatory cascade. Gene expression of CRP occurs mainly in hepatocytes, regulated by interleukin (IL)-6 originating from adipocytes and immune tissue. This cytokine and tumor necrosis factor (TNF)-alpha are candidate mediators for the proposed inflammatory link between increased body fat and induction of insulin resistance locally in adipocytes and in distant tissues [1,44,45]. Other inflammatory mechanisms, such as complement pathways, may also be important [46].
###end p 78
###begin p 79
###xml 183 184 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b003">3</xref>
###xml 185 187 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b047">47</xref>
Rodent models of obesity provide evidence that adipose expression of TNF-alpha is associated, reversibly, with insulin resistance and reduced glucose uptake and fatty acid oxidation [3,47].
###end p 79
###begin p 80
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b043">43</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b048">48</xref>
###xml 277 279 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b049">49</xref>
###xml 298 301 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 370 372 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b043">43</xref>
###xml 373 375 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b050">50</xref>
###xml 399 401 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b051">51</xref>
###xml 428 430 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050155-b052">52</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
In humans, SNPs in TNF have been linked with diabetes, obesity, and obesity phenotypes [43,48]. However, a short-term trial of the anti-TNF-alpha drug etanercept in individuals with the metabolic syndrome, did not increase insulin sensitivity despite a decrease in CRP levels [49]. With respect to IL6, there is evidence for associations of gene variants with diabetes [43,50], insulin sensitivity [51], and metabolic syndrome [52]. Whether obesity leads to insulin resistance primarily as a result of chronic low grade inflammation or metabolic alterations remains an important question.
###end p 80
###begin title 81
Supporting Information
###end title 81
###begin title 82
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Association between CRP Haplotypes and Serum CRP Concentration in NPHSII
###end title 82
###begin p 83
(40 KB DOC)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin title 85
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Confounding Variables by CRP Haplotype in NPHSII
###end title 85
###begin p 86
(54 KB DOC).
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
Whitehall II study: We thank all participating civil service departments and their welfare, personnel, and establishment officers; the Occupational Health and Safety Agency; the Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and all members of the Whitehall II study team.
###end p 88
###begin p 89
WTCCC: A full list of investigators who contributed to the generation of the data is available at .
###end p 89
###begin title 90
Abbreviations
###end title 90
###begin p 91
body mass index
###end p 91
###begin p 92
confidence interval
###end p 92
###begin p 93
C-reactive protein
###end p 93
###begin p 94
hemoglobin A1c
###end p 94
###begin p 95
homeostasis model assessment-insulin resistance
###end p 95
###begin p 96
hazard ratio
###end p 96
###begin p 97
linkage disequilibrium
###end p 97
###begin p 98
Northwick Park Heart Study II
###end p 98
###begin p 99
tumor necrosis factor
###end p 99
###begin p 100
Wellcome Trust Case Control Consortium
###end p 100
###begin title 101
References
###end title 101
###begin article-title 102
Obesity, inflammation, and insulin resistance
###end article-title 102
###begin article-title 103
Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity
###end article-title 103
###begin article-title 104
Inflammation and metabolic disorders
###end article-title 104
###begin article-title 105
Genetic variation, C-reactive protein levels, and incidence of diabetes
###end article-title 105
###begin article-title 106
The relation of markers of inflammation to the development of glucose disorders in the elderly
###end article-title 106
###begin article-title 107
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study
###end article-title 107
###begin article-title 108
###xml 83 88 <span type="species:ncbi:9606">women</span>
C-reactive protein is independently associated with fasting insulin in nondiabetic women
###end article-title 108
###begin article-title 109
###xml 63 68 <span type="species:ncbi:9606">women</span>
Inflammatory markers and risk of developing type 2 diabetes in women
###end article-title 109
###begin article-title 110
###xml 83 86 <span type="species:ncbi:9606">men</span>
C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998
###end article-title 110
###begin article-title 111
###xml 93 96 <span type="species:ncbi:9606">men</span>
C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men
###end article-title 111
###begin article-title 112
Targeting C-reactive protein for the treatment of cardiovascular disease
###end article-title 112
###begin article-title 113
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome
###end article-title 113
###begin article-title 114
What can mendelian randomisation tell us about modifiable behavioural and environmental exposures
###end article-title 114
###begin article-title 115
Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study
###end article-title 115
###begin article-title 116
Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels
###end article-title 116
###begin article-title 117
Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk
###end article-title 117
###begin article-title 118
Insight into the nature of the CRP-coronary event association using Mendelian randomization
###end article-title 118
###begin article-title 119
C-reactive protein and its role in metabolic syndrome: mendelian randomisation study
###end article-title 119
###begin article-title 120
###xml 127 130 <span type="species:ncbi:9606">man</span>
Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man
###end article-title 120
###begin article-title 121
Health inequalities among British Civil Servants: the Whitehall II study
###end article-title 121
###begin article-title 122
Cohort profile: the Whitehall II study
###end article-title 122
###begin article-title 123
Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study
###end article-title 123
###begin article-title 124
Instrumental variables regression with weak instruments
###end article-title 124
###begin article-title 125
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study
###end article-title 125
###begin article-title 126
Prospective relation of C-reactive protein with type 2 diabetes: response to Han et al
###end article-title 126
###begin article-title 127
Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002
###end article-title 127
###begin article-title 128
Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study
###end article-title 128
###begin article-title 129
###xml 107 110 <span type="species:ncbi:9606">men</span>
Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men
###end article-title 129
###begin article-title 130
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
###end article-title 130
###begin article-title 131
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes
###end article-title 131
###begin article-title 132
Variants in the CRP gene as a measure of life-long differences in average C-reactive protein levels: the Cardiovascular Risk in Young Finns Study
###end article-title 132
###begin article-title 133
###xml 20 25 <span type="species:ncbi:9606">human</span>
Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis
###end article-title 133
###begin article-title 134
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease
###end article-title 134
###begin article-title 135
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus
###end article-title 135
###begin article-title 136
A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein
###end article-title 136
###begin article-title 137
Relation of polymorphism within the C-reactive protein gene and plasma CRP levels
###end article-title 137
###begin article-title 138
Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level
###end article-title 138
###begin article-title 139
Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events
###end article-title 139
###begin article-title 140
Letter by Timpson et al regarding article, "Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level"
###end article-title 140
###begin article-title 141
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
###end article-title 141
###begin article-title 142
A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians
###end article-title 142
###begin article-title 143
Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes
###end article-title 143
###begin article-title 144
Adipose tissue, insulin action and vascular disease: inflammatory signals
###end article-title 144
###begin article-title 145
Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study
###end article-title 145
###begin article-title 146
Complement C3 is a risk factor for the development of diabetes: a population-based cohort study
###end article-title 146
###begin article-title 147
Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling
###end article-title 147
###begin article-title 148
Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome
###end article-title 148
###begin article-title 149
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Effects of etanercept in patients with the metabolic syndrome
###end article-title 149
###begin article-title 150
###xml 82 94 <span type="species:ncbi:9606">participants</span>
IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies
###end article-title 150
###begin article-title 151
Interleukin-6 gene polymorphism and insulin sensitivity
###end article-title 151
###begin article-title 152
Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites
###end article-title 152
###begin p 153
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. EJB, M. Kivimaki, DAL, MM, SEH, ADH, and M. Kumari designed the study. EJB, JAC, and MM analyzed the data. MM, GDOL, AR, TS, MGM, and M. Kumari collected data or did experiments for the study. EJB and M Kivimaki wrote the first draft of the paper. EJB, M. Kivimaki, DRW, DAL, GDS, JAC, MM, GDOL, AR, JPC, ADH, MGM, NJT, and M. Kumari contributed to writing the paper. M. Kivimaki helped in conducting the data analysis and interpretation. DRW contributed to the analysis of the data. MM supervised (scientific and administrative roles) the DNA extraction program and genotyping and was responsible for checking genotype results and in particular for verifying concordance of blind duplicates, establishing error rates, etc. GDOL supervised laboratory assays. TS selected CRP tag SNPs and conducted genotyping of these SNPs. NJT helped with analysis.
###end p 153
###begin p 154
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: The Whitehall II study has been supported by grants from UK Medical Research Council (MRC), British Heart Foundation, Health and Safety Executive, Department of Health, National Heart Lung and Blood Institute (HL36310), National Institute on Aging (AG13196), Agency for Health Care Policy Research (HS06516), and MacArthur Foundation Research Network on Socio-economic Status and Health. MGM is supported by an MRC Research Professorship. MGM and EJB are supported by the British Heart Foundation (BHF). Northwick Park Heart Study II (NPHSII) was supported by the UK Medical Research Council, the US National Institute of Health (grant NHLBI 33014), and Du Pont Pharma. TS was funded by a BHF PhD Studentship, and ADH by a BHF Senior Fellowship (FS/05/125). ADH acknowledges the generous support from the Rosetrees Trust. JAC and SEH are supported by the BHF (PG2005/014). Funding for the Wellcome Trust Case Control Consortium (WTCCC) project was provided by the Wellcome Trust under award 076113. No funding source had influence over the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 154
###begin p 155
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 155

